The influence of germline mutations on breast cancer
DOI:
https://doi.org/10.29289/2594539420230046%20Keywords:
genetic predisposition to disease, germ-line mutation, breast neoplasms, genes, genes, BRCA2, genes, BRCA1Abstract
The ability to evade protection mechanisms and uncontrolled cell growth can lead to the development of mutations, whether
somatic or germline, and consequently to the dreaded diagnosis of cancer. Breast cancer is considered the most common type
of cancer in women in several regions of Brazil, mainly in the South and Southeast, second only to non-melanoma skin cancer.
Approximately 5% to 10% of neoplasms are related to germline alterations that lead to hereditary predisposition. There is evidence
of an association with mutations in nine genes, the highest risk being breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2). Due to
its epidemiological importance, in this narrative review we observed the main genetic mutations and syndromes associated with
breast carcinoma, the recommendations for screening in high-risk patients, and the indication for genetic counseling. Bibliographic
research on the PubMed and Cochrane databases and analysis of the Guidelines Breast Cancer Risk Reduction and Breast Cancer
Screening and Diagnosis, from June 2022 to September 2023. In this review, we observed a greater influence of germline mutations
on breast cancer related to the genes BRCA1, BRCA2, PALB2, PTEN, CDH1, STK11 and, in Brazil, considered a country of ethnic-racial
diversity, to TP53. As cancer screening in the country is opportunistic, knowledge of germline mutations associated with breast
cancer offers specific screening recommendations for high-risk patients, indications for genetic counseling, and guidelines for
prophylactic surgery, in addition to impacting the formulation of public screening policies.
Downloads
References
1. Salzberg SL. Open questions: how many genes do we have? BMC Biol. 2018;16(1):94. https://doi.org/10.1186/s12915-018-0564-x
2. Jatoi I. Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition. Eur J Breast Health. 2018;14(4):189-93. https://doi.org/10.5152/ejbh.2018.4324
3. Carroll JC, Cremin C, Allanson J, Blaine S, Dorman H, Gibbons C, et al. Hereditary breast and ovarian cancers. Can Fam Physician. 2008;54(12):1691-2.
4. Instituto Nacional de Câncer (INCA). Estimativa 2023: Incidência de câncer no Brasil [Internet]. Brazil: INCA; 2023 [cited on Sep. 12, 2022]. Available at: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2023.pdf
5. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al, editors. GeneReviews. Seattle: University of Washington; 1993.
6. Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira RA, Ashton P. Recommendations for advancing the diagnosis and management of hereditary breast and ovarian cancer in Brazil. JCO Glob Oncol. 2020;6:439-52. https://doi.org/10.1200/jgo.19.00170
7. Guindalini RSC, Viana DV, Kitajima JPFW, Rocha VM, López RVM, Zheng Y, et al. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci Rep. 2022;12(1):4190. https://doi.org/10.1038/s41598-022-07383-1
8. Breast Cancer Association Consortium. Breast cancer risk genes: Associations analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428-39. https://doi.org/10.1056/nejmoa1913948
9. Chagpar, Anees B. Managing BRCA mutation Carriers. Cham: Springer; 2017.
10. Lalloo F, Evans DG. Familial Breast Cancer. Clin Gent. 2012;82(2):105-14. https://doi.org/10.1111/j.1399-0004.2012.01859.x
11. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. https://doi.org/10.1038/35021093
12. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336(20):1409-15. https://doi.org/10.1056/NEJM199705153362002
13. NCCN. Genetic/Familial high-risk assessment: breast, ovarian, and pancreatic. NCCN Clinical Practice Guidelines in Oncology; 2022.
14. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98(8):1457-66. https://doi.org/10.1038/sj.bjc.6604305
15. Hodgson SV, Maher ER. Practical guide to human cancer genetics. Cambridge: Cambridge University Press; 1999.
16. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750-69. https://doi.org/10.1016/S0140- 6736(20)32381-3Loibl, Sibylle; Poortmans, Philip; Morrow, Monica; Denkert, Carsten; Curigliano, Giuseppe. Breast cancer. The Lancet, [S.L.], v. 397, n. 10286, p.1750-1769,maio 2021. Elsevier BV. http://dx.doi.org/10.1016/s0140- 6736(20)32381-3
17. Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. 2021;384(5):440-51. https://doi.org/10.1056/NEJMoa2005936
18. Breast Cancer Association Consortium; Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384(5):428-39. https://doi.org/10.1056/NEJMoa1913948
19. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54(5):1298-304.
20. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology – Breast Cancer. National Comprehensive Cancer Network; 2024.
21. Lowry KP, Geuzinge HA, Stout NK, Alagoz O, Hampton J, Kerlikowske K, et al. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis. JAMA Oncol. 2022;8(4):587-96. https://doi.org/10.1001/jamaoncol.2021.6204
22. Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collée JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136(3):668-77. https://doi.org/10.1002/ijc.29032
23. Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol. 2024;42(5):JCO2302225. https://doi.org/10.1200/JCO.23.02225
24. Brasil. Lei nº 11.664, de 29 de abril de 2008. Dispõe sobre a efetivação de ações de saúde que assegurem a prevenção, a detecção, o tratamento e o seguimento dos cânceres do colo uterino e de mama, no âmbito do Sistema Único de Saúde – SUS. Diário Oficial da União. 2008.
25. Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, et al. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Res Treat. 2019;173(2):385-95. https://doi.org/10.1007/s10549-018-5015-4
26. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77-84. https://doi.org/10.1056/NEJM199901143400201
27. Instituto Nacional de Câncer. Rede nacional de câncer familial: manual operacional. Rio de Janeiro: Instituto Nacional de Câncer; 2009. Brazil: Ministério da Saúde.
28. Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel Planche G, et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 2008;261(1):21-5. https://doi.org/10.1016/j.canlet.2007.10.044
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Maria Fernanda Sperotto Valadares Gontijo, Luísa Lazarino, Avelar Caroline, João Pedro Apolinário, Galvão Henrique, Anna Dias Salvador, José Tadeu Campos de Avelar
This work is licensed under a Creative Commons Attribution 4.0 International License.
